GSK - GlaxoSmithKline plc
| Previous Close | 38.880 |
| Open | 39.540 |
| Bid | 39.600 x 1800 |
| Ask | 39.610 x 3100 |
| Day's Range | 39.420 - 39.760 |
| 52 Week Range | 34.520 - 42.360 |
| Volume | 1,772,130 |
| Avg. Volume | 2,458,250 |
| Market Cap | 95.435B |
| Beta (3Y Monthly) | 0.56 |
| PE Ratio (TTM) | 44.77 |
| EPS (TTM) | 0.884 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | 1.98 (5.18%) |
| Ex-Dividend Date | 2018-08-09 |
| 1y Target Est | 44.30 |
- Yahoo Finance•19 hours ago
Trump administration: Drug makers should disclose prices in TV ads
just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.
Market Realist•4 days agoA Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.
Market Realist•4 days agoHow Analysts View Bausch Health in October
In the second quarter, Bausch Health (BHC) reported net income and diluted EPS of -$873.0 million and -$2.49, respectively, compared to -$38.0 million and -$0.11 in the second quarter of 2017. In the first half, Bausch Health generated net income and diluted EPS of -$3.45 million and -$9.84, respectively, compared to $590.0 million and $1.68 in the first half of 2017.
- Market Realist•5 days ago
Analysts’ Estimates and Ratings for Novartis in October
Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
- Market Realist•6 days ago
A Closer Look at Novartis’s Innovative Medicines Segment
Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
- Market Realist•6 days ago
How Novartis’s Businesses Have Been Performing
Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business
- Market Realist•7 days ago
A Look at Novartis’s Valuation on October 9
Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue compared to $12.2 billion in the second quarter of 2017.
- American City Business Journals•8 days ago
Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area
Orchard Rx Ltd., a London-based gene therapy company targeting "bubble boy" disease and other rare genetic conditions, wants to raise $172.5 million through an initial public offering that in part will bankroll a key Bay Area expansion. Orchard, whose shareholders include drug giant GlaxoSmithKline plc (NYSE: GSK), is the latest biotech company to take advantage of Wall Street's open cash window. It filed its IPO plans Thursday, less than two months after raising $148 million in an oversubscribed Series C round.
- Zacks•11 days ago
Merck Reports Positive Efficacy Data from Phase III HIV Study
Merck (MRK) reports positive data from the phase III DRIVE-AHEAD study, evaluating Delstrigo in treatment-naive adults with HIV-1 infection.
- Zacks•11 days ago
Gilead Announces Positive Data From Ongoing Biktarvy Study
Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.
Market Realist•11 days agoAnalyzing Seattle Genetics’ Key Collaborations
Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries. Adcetris was approved in Japan for treating frontline Hodgkin lymphoma. Seattle Genetics has a global collaboration with Takeda Pharmaceutical (TKPYY) to develop and commercialize Adcetris. While Seattle Genetics retains rights for the drug in the United States and Canada, Takeda has the rights for the drug in the rest of the world. Takeda pays Seattle Genetics a royalty.
- Zacks•12 days ago
J&J's Phase III Data Shows Switch to its HIV Drug Beneficial
Data from the 96-week long phase III EMERALD study shows that switching to J&J's (JNJ) Symtuza maintains high virologic suppression.
- Market Realist•12 days ago
GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018
GlaxoSmithKline (GSK) segregates its business portfolio into three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare. As a British multinational company, GlaxoSmithKline reports its revenues in pounds sterling. The chart below compares GlaxoSmithKline’s EPS and revenues since the first quarter of 2017, as well as its estimates for the third quarter.
- The Wall Street Journal•13 days ago
[$$] Boston Pharma Adds to War Chest in Pacts With Novartis, GlaxoSmithKline
Boston Pharmaceuticals Inc., a startup backed with a $600 million funding commitment from a single investor, is bulking up its portfolio of potential medications. PLC to add to its portfolio, securing three anti-infective programs from Novartis and five products from GSK, including drugs that could treat acne and irritable bowel syndrome.
